UDG Healthcare announces Independent Director Shane Cooke as next Board Chairman

– IRELAND, Dublin –  UDG Healthcare plc (LON: UDG), a leading international healthcare services provider, today announced the appointment of Independent Director Shane Cooke as Board Chair effective from 1 October 2020, succeeding Peter Gray, who retires from the Board on 30 September 2020.

Peter Gray, current Board Chair said: “Following a robust and thorough selection process led by our Senior Independent Director, Myles Lee, I am delighted to be handing over to Shane in October. His breadth of experience, particularly in the US healthcare market, will be a great asset in guiding the board of UDG as it continues to chart its strategic course. “

About Shane Cooke

Shane joined the UDG Healthcare plc Board on 1 February 2019 and was later appointed Chair of the Risk, Investment and Financing Committee on 28 January 2020. He is currently a Non-Executive Director of NASDAQ-listed Alkermes plc, having previously held the position of President from September 2011 until his retirement in 2018. Prior to this, Shane spent over 10 years as Chief Financial Officer of Elan Corporation plc and from 2007 he was also Head of Elan Drug Technologies. Prior to Elan he held the role of Chief Executive Officer of Pembroke Capital Ltd., an aviation leasing company of which he was a founder. Shane currently also currently serves as a Non-Executive Director on the Board of Prothena Corporation plc, and of Endo International plc, both publicly quoted companies.

About UDG Healthcare plc:

UDG Healthcare plc is an FTSE 250 global leader in the healthcare advisory, communications, commercial, clinical and packaging services industries. UDG employs 9,000 people across operations in 29 countries, delivering services in over 50 countries.

Operating across two divisions, Ashfield and Sharp, UDG provides outsourced services which enable over 300 healthcare companies from large pharmaceutical to small biotech to bring their products to market.

Ashfield is a global leader in commercialisation services for the pharmaceutical and healthcare industry, operating across three business areas: Advisory, Communications and Commercial & Clinical. The division focuses on supporting patients to access and adhere to their medications and educating and communicating effectively with healthcare professionals and patients on these products at all stages of the product life cycle. Ashfield provides strategic consulting, advisory services, patient solutions, scientific and creative communications, PR, on-demand advertising services, field and contact centre sales teams, and medical information and event management services.

Sharp is a global leader in contract commercial packaging, clinical, manufacturing and technology services for the pharmaceutical and biotechnology industries, operating from eight state-of-the-art facilities in the US and Europe.

For more information: https://www.udghealthcare.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.